Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
56 hedge funds and large institutions have $16M invested in Aralez Pharmaceuticals Inc. in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 13 closing their positions.
5% less call options, than puts
Call options by funds: $135K | Put options by funds: $142K
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
6% less capital invested
Capital invested by funds: $17.1M → $16M (-$1.11M)
11% less funds holding
Funds holding: 63 → 56 (-7)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$579K |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$494K |
| 3 |
Renaissance Technologies
New York
|
+$303K |
| 4 |
SM
Salzhauer Michael
|
+$199K |
| 5 |
BAS
Brown Advisory Securities
Baltimore,
Maryland
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
PAR Capital Management
Boston,
Massachusetts
|
-$2.64M |
| 2 |
Goldman Sachs
New York
|
-$332K |
| 3 |
BMCM
Bryn Mawr Capital Management
Philadelphia,
Pennsylvania
|
-$260K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$230K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$155K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
D.E. Shaw & Co
New York
| – | -$150K | -105,410 | Closed |
|
52
Millennium Management
New York
| – | -$93K | -65,770 | Closed |
|
|
JG
53
Jefferies Group
New York
| – | -$25K | -17,300 | Closed |
|
|
TSS
54
Two Sigma Securities
New York
| – | -$24K | -16,550 | Closed |
|
|
BAM
55
Berkshire Asset Management
Wilkes Barre,
Pennsylvania
| – | -$21K | -15,000 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$7K | -4,916 | Closed |
|
57
UBS Group
Zurich,
Switzerland
| – | -$6K | -4,371 | Closed |
|
|
DOA
58
D'Orazio & Associates
Falls Church,
Virginia
| – | -$1K | -1,006 | Closed |
|
59
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$220 | -126 | -93% |
|
60
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$312 | +179 | New |
|
ARLZ Hedge Fund Activity: Q1 2018 in Review
56 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q1 2018, worth a combined $16M — down 6.5% from $17.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ARLZ and 6 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 14 added.
The largest buyer was Wells Fargo, adding an estimated $579K. The largest seller was PAR Capital Management, cutting an estimated $2.64M.
- 56 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q1 2018, down from 63 in Q4 2017.
- Funds reported $16M of Aralez Pharmaceuticals Inc. stock for Q1 2018, down 6.5% quarter-over-quarter.
- 6 funds opened new Aralez Pharmaceuticals Inc. positions in Q1 2018 and 13 closed out, a net change of -7 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q1 2018 was Wells Fargo, an estimated $579K added.
- The largest Aralez Pharmaceuticals Inc. seller in Q1 2018 was PAR Capital Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q1 2018.